Wedbush analyst Gerald Pascarelli initiated coverage of Curaleaf with an Outperform rating and $8.50 price target. Curaleaf is the largest U.S. cannabis operator and should be well positioned to realize incremental benefits from the rollout of adult use sales in new states in addition to benefiting from better performance in its many legacy markets, Pascarelli tells investors in a research note. He expects the company to be a net share gainer and outpace the broad industry.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CURLF:
- CURLF, GTBIF, or IIPR: Which “Strong Buy” Cannabis Stock has Higher Upside Potential?
- Curaleaf (TSE:CURA) Misses Q3-2022 Earnings Estimates, but There’s Potential Here
- Curaleaf Reports Third Quarter 2022 Results
- Cannabis Stocks are on a High after Biden Calls for Favorable Reforms
- Curaleaf Completes Acquisition of Tryke Companies